Earlier this week, small capCell MedX Corp (OTCQB: CMXC) announced that it has completed its registration process with the FDA and has initiated an application process to receiveclearance for use of its eBalance device as Class II non-exempt device. Cell MedX Corpsebalance technology is designed to alleviatecomplications associated with certain medical conditions by reinvigorating the electrochemical system that naturally occurs in healthy cells.
In observational trials, the Companyhas alreadyseen that by increasing cell activity, many of the conditions prevalent in suffering individuals maystop and in some instances actually reverse. Pain is reduced, and non-healing wounds mayheal. For diabetics in particular, this can mean that less insulin may be required on a daily basis, pain medication related to neuropathy may be reduced or potentially no longer needed, and limb degradation due to neuropathy may be slowed or reversed allowing legs and feet to heal.
The current Observational Clinical Trial is assessing the impact of three months of eBalance therapy as an adjunct treatment, on HbA1c in Type 1 and Type 2 diabetics. The secondary endpoints of the Trial will observe changes from baseline and medical history in the following;
Insulin sensitivity Diabetic neuropathy Diabetic foot pain and numbness Wound healing Blood pressure Kidney function Any other changes reported by patients
The Company stated that its ongoing clinical observational trial is progressing as expected and as of this week,the group of study participants had been increased to 27 with 18 subjects having received their first eBalance treatments. The Company expects that all 30 subjects will be initiated into the study by early April.
Thisebalancetechnology will eventually form the basis for a product line that will be available to aid in the management of diabetes mellitus (T1DM and T2DM) and its complications, both as a professional clinic-based as well as a home use device.
Cell MedX Corp itself is an early development stage bio-tech company focused on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness and alleviate complications associated with medical conditions including, but not limited to, diabetes, Parkinsons disease, high blood pressure. Itsalso listed on the OTCQB the middle tier of the over-the-counter (OTC) marketwhich isintended for entrepreneurial and development stageUS and international companies.Thereareno financial or qualitative standards to belisted on the OTCQB market, but OTCQB stocks are said to be committed to both disclosure and transparency. They are alsoconsidered to be less speculative in nature than stocks trading on the OTC Pink market (the bottom tier of the OTC market).